Vero

Vero Biotech is a commercial-stage biopharmaceutical company focused on the design, development, and commercialization of innovative therapies for patients with pulmonary hypertension and other acute respiratory conditions. The company's flagship product, Genosyl, is the first tankless inhaled nitric oxide delivery system approved by the FDA, providing a portable and user-friendly alternative to traditional bulky cylinders. By utilizing a proprietary cassette-based technology, Vero Biotech simplifies the administration of nitric oxide in hospital settings and potentially in the home. The company continues to expand its pipeline to address unmet needs in neonatal intensive care and adult cardiac surgery.